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Highlights 
 In a Geriatric Evaluation and Management Unit (GEMU), sarcopenia prevalence 
is high (405) 
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 Sarcopenia was associated with dependency in both Activities of Daily Living 
(ADLs) and Instrumental ADLs.  
 Patients with sarcopenia were twice as likely to die in the 12-months post-
hospitalisation 
 Sarcopenia was not associated with admission to an Emergency Department 
(ED) in the 12-months post-hospitalisation. 
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Introduction: Sarcopenia poses a significant problem for older adults, yet very little is 
known about this medical condition in the hospital setting. The aims of this hospital-
based study were to determine: (i) the prevalence of sarcopenia; (ii) factors associated 
with sarcopenia; and (iii) the association of sarcopenia with adverse clinical outcomes 
post-hospitalisation.  
Methods: This is a longitudinal analysis of consecutive patients aged ≥70 years 
admitted to a Geriatric Management and Evaluation Unit (GEMU) ward. Sarcopenia 
was classified using the European Working Group on Sarcopenia in Older People 
(EWGSOP) algorithm, which included: handgrip strength, gait speed, and muscle mass 
using Bioelectrical Impedance Analysis (BIA). Outcomes were assessed at 12-months 
post-hospital discharge, and included both mortality and admission to a hospital 
Emergency Department (ED). Kaplan-Meier methods were used to estimate survival, 
with Cox proportion hazard models then applied. All regression analyses controlled for 
age, sex, and co-morbidity. 
Results: 172 patients (72% female) with a mean (SD) age of 85.2 (6.4) years were 
included. Sarcopenia was present in 69 (40.1%) of patients. Patients with sarcopenia 
were twice as likely to die in the 12-months post-hospitalisation (HR, 95% CI = 2.23, 
1.15-4.34), but did not have an increased likelihood of ED admission. 
Conclusions: Sarcopenia showed an independent association with 12-month post-
hospital mortality in older adults. With the new recognition of sarcopenia as a medical 
condition with its own unique ICD-10-CM code, awareness and diagnosis of sarcopenia 
in clinical settings is paramount. 
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Introduction  
Sarcopenia, an age-related condition characterized by a decline in muscle mass 
and physical function (1, 2), has recently been recognised with its own International 
Classification of Disease (ICD-10CM) code [M62.84] (3). With this new recognition, 
sarcopenia awareness and management is urgently warranted. Sarcopenia is particularly 
problematic in the hospital setting, where it can adversely affect patient outcomes (4-8). 
Hospitalisation exacerbates sarcopenia which in turn, can increase an older adult’s risk 
of functional decline, falls and mortality (9). Indeed, many chronic conditions have a 
worsened prognosis when a patient is sarcopenic (5, 10-14). Sarcopenia is also common 
in hospitals, with around 40% of older patients presenting with the condition (10, 14, 
15). 
 
To measure sarcopenia, there has been a widespread uptake of the sarcopenia 
algorithm from the European Working Group on Sarcopenia in Older People 
(EWGSOP) (2, 7, 16-21). This highly validated algorithm incorporates both handgrip 
strength and gait speed into its sarcopenia classification protocol (2, 22, 23). Several 
recent studies have applied the EWGSOP algorithm in the hospital setting, where it has 
been predominately used to assess both the prevalence of sarcopenia, and its association 
with mortality (4-8). The majority of these studies have focused on specific populations 
of older patients, or those patients in acute care.  
 
For optimal care of older patients, Comprehensive Geriatric Assessment (CGA) 
followed by appropriate care planning is crucial. Such services can be provided in 
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specialised Geriatric Evaluation and Management Units (GEMU). GEMUs are designed 
to maximise the functional independence of older patients whose geriatric conditions 
benefit from comprehensive assessment and management - such conditions include falls 
risk, polypharmacy, cognitive decline, undernutrition, frailty, and social and functional 
impairment (24, 25). GEMUs are geriatrician-led, and provide multi-disciplinary care 
from physiotherapists, speech pathologists, pharmacists, dieticians, occupational 
therapists, psychologists/psychiatrists, and social workers (25). Patient outcomes are 
substantially improved in GEMUs, including: discharge directly back home, functional 
improvement, better pain management, and enhanced mental health (24, 25). 
 
To date, very little is known about the prevalence of sarcopenia in GEMUs, and 
its impact on adverse clinical outcomes. Therefore, using the EWGSOP algorithm to 
identify sarcopenia, this study aimed to: (i) to determine the prevalence of sarcopenia; 
(ii) identify factors associated with sarcopenia; and (iii) examine the association of 
sarcopenia with 12-month GEMU discharge outcomes, including mortality, and 
admission to a hospital Emergency Department (ED).  
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Methods 
Study Sample 
This was a secondary, longitudinal analysis of consecutive patients aged 70 
years and older recruited between October 2010 and December 2011 from the GEMU at 
The Queen Elizabeth Hospital (TQEH) in Adelaide, South Australia. A complete 
description of the study protocol is available elsewhere (26). Data were collected from 
either the older adult (or proxy) in the first 72 hours of GEMU admission. This study 
was approved by the Human Research Ethics Committee (TQEH) and all patients (or 
their legal proxy) signed an informed consent form (Protocol Number: 2010105). The 
majority of patients were transferred to the GEMU from the Acute Medical Unit (short 
stay <72 hours) after identification by TQEH geriatric service. All patients in the 
GEMU received daily physiotherapy sessions, including individual sessions and/or 
group physical activity classes. The study adhered to the ethical standards from the 
2000 Declaration of Helsinki.  
 
Measurements 
Patient hospital records were reviewed to obtain data on cognition (measured by 
the Mini-Mental State Examination [MMSE]) (27), co-morbidity (Charlson’s Co-
morbidity Index [CCI]) (28), Activities of Daily Living (ADLs), and Lawton’s 
instrumental ADLs (IADLs) (29), depression (Geriatric Depression Scale, 15-item 
[GDS-15]) (30), falls history, polypharmacy (≥ 6 medications), and serum levels of C-
reactive protein (CRP). Patient (or proxy) interview was used to collect data on socio 
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demographics and general health status, including appetite/weight loss risk screened 
using the Simplified Nutritional Appetite Questionnaire (SNAQ) (31). Standing height 
and seated weight were measured and Body Mass Index (BMI) (weight/height
2
) 
computed. Handgrip strength was measured using a Smedly spring-type hand held 
dynamometer with adjustable hand settings, and the best result of three trials with the 
dominant hand was used for analysis. Gait speed was measured as the time taken to 
walk 6m at usual speed, with or without a walking aid. Bioelectrical Impedance 
Analysis (BIA) was measured using a Quantum II BIA Analyser, RJL system, and 
Janssen prediction equations (as per the recommendation of the BIA system 
manufacturer) were used to convert BIA resistance and reactance values to Skeletal 
Muscle Mass (32). One researcher conducted all patient measurements and 
patient/proxy interviews. 
 
Sarcopenia classification 
Sarcopenia was classified using the EWGSOP algorithm, in which participants 
were classified as sarcopenic if they had low muscle mass, plus one or both of low 
muscle strength and low physical performance (2). Low muscle mass was defined 
according to EWGSOP BIA cut-off points, which in turn were based on the National 
Health and Nutrition Examination Survey (NHANES) recommended cut-off points: 
10.76kg/m
2 
and 6.76kg/m
2 
for men and women respectively (2). Low muscle strength 
was defined as handgrip strength in the lowest quintile for BMI and sex in our study 
cohort. Low physical performance was defined as a gait speed in the lowest quintile for 
BMI and sex in the cohort. The lowest quintile for both gait speed and grip strength 
were used because the average age of our population was over 85 years, which is much 
higher than the average age used in the normative charts for the EWGSOP  
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Outcome measures 
All study outcomes were assessed at 12-months post-hospital discharge, and included 
the following:  
(i) Mortality, verified using Australian Death Registry data. 
(ii) Admission (inpatient admission) to a hospital Emergency Department (ED).  
 
Statistical analyses 
Descriptive variables were presented as frequencies for categorical variables, as 
mean (standard deviation [SD]) for normally distributed continuous variables, and 
median (interquartile range) for non-normally distributed continuous variables. Two 
types of analyses were performed. Firstly, univariate analyses were performed to 
determine which factors were associated with sarcopenia: t-tests and chi-square tests 
were performed for continuous and categorical variables respectively. Secondly, 
Kaplan–Meier survival curves were plotted for all three study outcomes, with Cox 
Proportional Hazard Tests (with Hazard Ratios [HRs]) then performed to determine the 
association of sarcopenia with both study outcomes. Both regression models were 
adjusted for age, sex and CCI.  
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For outcomes not involving mortality, those patients who died before follow-up 
were excluded from analyses. Data analyses were performed using SPSS 21.0 (SPSS 
Inc., Chicago, Illinois), with P < 0.05 indicating clinical significance. 
 
 
 
 
Results 
From 427 new consecutive patients admitted to the GEMU, 172 patients were 
recruited. Exclusion reasons were: patient (or proxy) did not speak English (n=67), 
dementia/unresolved delirium within 72 hours of GEMU admission without a proxy 
(n=77), GEMU physician advised against patient inclusion (n = 11), missed by 
researcher (n=4), or the patient did not wish to be involved in the study (n=63). The 
most common primary GEMU admission diagnoses were: chronic conditions (71 
patients, 41%), infection (52 patients, 30%), and injury/musculoskeletal condition (28 
patients, 16%).  
The sarcopenia categorisation for study patients using the EWGSOP algorithm is 
depicted in Figure 1. Sarcopenia was present in 69 (40%) patients. Table 1 displays the 
baseline characteristics of included patients stratified by sarcopenia status. From this 
table, it can be seen that patients with sarcopenia were more likely to have lower levels 
of function for both ADLs and IADLs upon GEMU admission, but did not differ in 
other baseline variables, including appetite, compared with their non-sarcopenic 
counterparts.  
Regarding study outcomes 12-months post-hospitalisation, 36 (21%) patients 
died, 121 (74%) were admitted into an ED, and 66 (59%) were admitted to an ED as a 
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result of a fall.  The Kaplan-Meier survival curves for all outcomes are plotted in Figure 
2. The results of the Cox Regression models (controlling for co-variates) comparing the 
Kaplan-Meier curves for both study outcomes are shown in Table 2. Patients with 
sarcopenia were statistically more likely to die in the 12 months post-hospitalisation, 
with HR 2.23 (95% CI = 1.15-4.34). However, there was no statistically significant 
association between sarcopenia and ED admission. Of note, there was a high rate of 12-
month ED admission (>90%) for both sarcopenic and non-sarcopenic patients (see 
Figure 2). 
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Discussion 
The present study is the first, to our knowledge, to investigate sarcopenia 
determinants, prevalence and outcomes in a GEMU. Sarcopenia prevalence was high 
(40%), and showed a strong relationship with dependency in both ADLs and IADLs. 
There was no association between sarcopenia and appetite, CRP levels, depression, falls 
history, cognition, CCI, or polypharmacy. Patients classified as sarcopenic were twice 
as likely to die in the 12-months post-hospitalisation, but did not have an increased 
likelihood of 12-month ED admission.    
 
The high prevalence of sarcopenia found in the present study was similar to that 
found by Sánchez-Rodríguez and colleagues in their study of older patients in sub-acute 
care, which also used the EWGSOP algorithm to classify sarcopenia (20). Similarly, the 
close association of sarcopenia and mortality in our study concurs with many studies, 
both in the acute-care setting (4, 33) and in the community (22, 34), although not all 
studies have reported an association (20). It could likely be that the association of 
sarcopenia with mortality is transient, with nutritional, physical and pharmaceutical 
interventions likely to ameliorate the association (18, 35).   
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This study’s finding that sarcopenia was not associated with 12-month ED 
admission differs from the findings of a recent study by Gariballa & Alessa (5), who 
suggested that sarcopenic patients in acute care are more likely to be admitted to an ED 
in the 6-months post-hospitalisation. This difference in findings could likely reflect our 
longer follow-up period, the older average of our patients (85 years vs 79 years), the 
different recovery trajectories of sarcopenic patients in acute care compared with those 
in sub-acute care, or because their modified version of the EWGSOP algorithm did not 
use gait speed. Alternatively, it could be because of the high rate of ED admissions in 
both sarcopenic and non-sarcopenic patients – indicating that GEMU patients were a 
vulnerable population, regardless of sarcopenia status.  
 
The lack of association between appetite and sarcopenia in the present study was 
unexpected. Low appetite is generally considered to be a risk factor for sarcopenia, at 
least in community dwelling older adults (37). A possible explanation for this lack of 
association is that hospitalisation itself was affecting the appetite of all patients, not just 
those classified as sarcopenic. 
 
Managing sarcopenia could further prevent disability caused directly through 
sarcopenia, or by slowing its progression to frailty (38-40).  Additionally, if sarcopenia 
is detected early, it can potentially be managed proactively with nutritional, physical 
activity, and/or pharmacological interventions (18, 35). Importantly, the recognition of 
sarcopenia as a medical condition by the ICD will progress both the clinical 
management and research surrounding this condition. For instance, targeted nutritional 
interventions may be developed, and the condition will be reported on patient medical 
records.  
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The present study had many strengths, including its lack of inter-tester bias, the 
recruitment of consecutive patients and the comprehensive dataset. The study however 
did have its limitations, including the small sample size, and the use of BIA to measure 
muscle mass, the latter of which can be affected by many factors in older patients, 
including oedema and polypharmacy. Nonetheless, the use of BIA in older patients is a 
rapid, easy and inexpensive means to measure skeletal muscle mass, and been used in 
previous large-scale studies in both hospitals and in the community (4, 7, 21, 41). 
Importantly, the use of the tailored cut-off points (lowest quintile) for handgrip strength 
and gait speed in our current study would have likely under-estimated the actual 
prevalence of sarcopenia. Our study was also observational by design, so no 
assumptions of causation can be made. Also of note, the majority of patients in the 
present study were in hospital for three days prior to GEMU admission, and 
accordingly, they may have experienced muscle mass/functional decline prior to GEMU 
admission.  
 
This study highlights the high prevalence of sarcopenia in GEMU patients, and 
its strong association with mortality post-hospitalisation. The recent recognition of 
sarcopenia as a medical condition with its own unique ICD-10-CM code, is a much 
needed first step to identifying, managing and treating this condition. Future research 
with larger sample sizes should be performed to determine the association of sarcopenia 
with diverse adverse clinical outcomes. More comprehensive methods for muscle mass 
assessment, such as dual-energy X-ray absorptiometry, and computed tomography, 
should be used for this purpose. Randomized controlled trials in both the acute and sub-
acute care settings are also needed to determine the optimal treatment/management of 
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sarcopenia patients, particularly with regards to pharmacological, nutritional, and 
physical activity interventions (18, 35). The predictive ability of change in sarcopenia 
status across hospitalisation should also be considered for additional research.  
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Tables and Figures 
 
Table 1. Baseline Characteristics of GEMU Patients Stratified by Sarcopenia Status 
(n=172) 
Variable 
Total  
n (%) 
Sarcopenic 
(n=69) 
Not Sarcopenic 
(n=103) 
P 
Age
†
 85.2 (6.4) 85.5 (6.8) 85.0 (6.2) 0.592 
Married 59 (34.3) 26 (37.7) 33 (32.0) 0.445 
Lives alone 105 (61.1) 37 (53.6) 68 (66.1) 0.102 
Completed higher education 15 (8.7) 6 (8.7) 9 (8.7) 0.992 
Charlson’s Co-morbidity Index ‡   3 (0-12) 2.5 (0-8) 3 (0-12) 0.481 
ADL
‡
 3 (0-7) 1 (0-7) 4 (0-7) <0.001 
IADL
‡
 3 (0-8) 2 (0-8) 3 (0-8) <0.001 
Current smoker 9 (5.2) 2 (2.9) 7 (6.8) 0.261 
Currently drinks alcohol 19 (11.1) 9 (13.0) 10 (9.7) 0.494 
MMSE < 24  38 (22.1) 19 (27.5) 19 (18. 5) 0.159 
GDS score
†
 5.68 (4.6) 6.39 (5.0) 5.21 (4.4) 0.103 
SNAQ score
†
 13.14 (3.2) 12.76 (3.6) 13.39 (2.9) 0.206 
Fall in the 12 months before hospital 54 (31.4) 18 (26.1) 36 (35.0) 0.220 
Polypharmacy (≥ 6 medications) 147 (85.5) 59 (85.51) 88 (85.44) 0.990 
C-reactive protein mg/L
†
 3.39 (4.0) 3.69 (4.12) 3.18 (3.96) 0.416 
† 
Mean (SD) 
‡
 Median (interquartile range) 
ADL= Activities of Daily Living, IADL= Instrumental Activities of Daily Living, 
MMSE= Mini Mental Status Examination, GDS = Geriatric Depression Scale, SNAQ = 
Simplified Nutrition Appetite Questionnaire 
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Figure 1. EWGSOP Sarcopenia Algorithm 
Categorization of sarcopenia is as follows: older adults with abnormal gait speed and 
abnormal muscle mass (n=34) plus older adults with normal gait speed but abnormal 
handgrip strength and abnormal muscle mass (n=35) 
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Figure 2. Kaplan-Meier Curves for GEMU patients (n=172): a) Mortality, and b) 12-
Month admission to a hospital via the Emergency Department Visit.  
Analysis time = days, and all patients were followed up for 365 days. The steepest 
decline curve for all outcomes was for sarcopenic patients. 
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Table 2. Results of Cox Regression Models showing the Association of Sarcopenia 
with Study Outcomes (n=172)
† 
 
Outcomes Adjusted HR, (95% CI)‡ P 
12-Month mortality  2.23 (1.15 - 4.34) 0.018 
12-Month ED admission 0.92 (0.62 - 1.37) 0.703 
† Adjusted for age, sex and Charlson’s Comorbidity Index 
‡Adjusted Hazard Ratios Correspond to Sarcopenia Status 
ED = Emergency Department 
 
